🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Data on outcome of patients with Stage IIIb AL #Amyloidosis treated with Dara-VCD CAMP@CUIMC Herbert Irving Comprehensive Cancer Center

Join us CAMP@CUIMC Herbert Irving Comprehensive Cancer Center for Amyloidosis Support Group meeting (both AL and ATTR) in June!!

We are excited to host in-person Amyloidosis Support Group this week on 6/24!! Amyloidosis experts will speak on the diagnosis and management of AL and ATTR amyloidosis and answer patients' questions. Suzanne Lentzsch, MD, PhD mathew.maurer Markus Y. Mapara 🇺🇦 Amyloidosis Support Muriel Finkel

As #ASH23 is upon us, I wanted to share some key abstracts pertaining to non-myeloma plasma cell disorders (𝐀𝐋 𝐀𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬, 𝐌𝐆𝐔𝐒, 𝐒𝐌𝐌, 𝐌𝐆𝐑𝐒, 𝐚𝐧𝐝 𝐨𝐭𝐡𝐞𝐫𝐬) that caught my attention! Follow along for the 🧵

Check out our paper on teclistamab in AL amyloidosis! Amyloidosis Research Consortium Amyloidosis Support Muriel Finkel Suzanne Lentzsch, MD, PhD Herbert Irving Comprehensive Cancer Center

Join us at CAMP@CUIMC Herbert Irving Comprehensive Cancer Center for a comprehensive update on management if AL Amyloidosis! Suzanne Lentzsch, MD, PhD mathew.maurer

With #ASH24 around the corner, here are my picks on clinically relevant abstracts in #MultipleMyeloma, AL #Amyloidosis, and other plasma cell disorders 🧵

In AL #Amyloidosis, we are no longer in an era of ~30% early mortality! New data by George Mellgard shows 6 mo early mortality ~11% in 335 pts with Dara-VCd/Dara-Vd (44% stage IIIa/IIIb) Predictors of EM-Age, ECOG/NYHA, NT-proBNP & absence of t(11;14)! #ASH24

This is an important trial that will define the future of Auto-Transplant in AL Amyloidosis! Now enrolling at Herbert Irving Comprehensive Cancer Center CAMP@CUIMC!

Led by Michael Hughes, clinically relevant data on modern-era outcomes of #Myeloma Cast Nephropathy (mostly excluded from clinical trials) Herbert Irving Comprehensive Cancer Center! 4 key takeaways: ✅Renal ORR/Renal CR: ~75%/33% ✅No increase in early mortality with MCN ✅Most eGFR improvement within 1

Longest follow up of phase III clinical trials in myeloma #mmsm UAMS Myeloma Center Blood Advances ➡️ ashpublications.org/bloodadvances/… ✅Median survival >13 years ✅ 41% of patients remained disease free and off therapy with fixed-duration therapy in standard-risk MM ✅Myeloma is curable

Important paper on outcomes of myeloma kidney without PLEX in the modern era! With several negative controlled trials of PLEX even in the pre-daratumumab era, hard to justify its role in the current treatment landscape, especially if immediate access to anti-CD38mAb. Congrats

Today's MM Paper of the Week! Raj Chakraborty The IMROZ trial found that a 4-drug combination with an anti-CD38 monoclonal antibody improves progression-free survival over the 3-drug VRd regimen in transplant-ineligible multiple myeloma patients. bit.ly/4humKmv

Important thread by Sigurdur Kristinsson highlighting why current evidence is insufficient for screening in MM! We would need an RCT showing all-cause mortality benefit, which iStopMM will answer!

Congrats Suzanne Lentzsch, MD, PhD!!

'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on Ben Derman 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk